It may prevent or reverse dyskinesia (involuntary movements) caused by standard Parkinson's medications. 2. Alzheimer’s Disease (AD) MSDC-0160 - Metabolic Solutions Development Company

In preclinical models, MSDC-0160 protected dopaminergic neurons, improved motor function, and reduced neuroinflammation.

By modulating mitochondrial metabolism, it prevents the over-activation of mTOR , a key nutrient sensor that, when overactive, is linked to neurodegeneration and inflammation. 🧠 Therapeutic Applications

MSDC-0160 is a novel, clinical-stage drug candidate originally developed for . It is the prototype of a new class of insulin sensitizers called mTOT Modulators (Mitochondrial Target of Thiazolidinediones). Unlike first-generation insulin sensitizers like pioglitazone, MSDC-0160 is PPAR